GeneTx and Ultragenyx Announce Investigational New Drug
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES SALE OF ITS SHARES IN GENETX TO ULTRAGENYX
Ultragenyx Pharmaceutical, Inc. Aktie News
Investors & Media—Ultragenyx Pharmaceutical Inc.
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy - Jett Foundation
Ultragenyx Announces Proposed Public Offering of Common Stock | RARE Stock News
Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology | World Pharma Today
GeneTx and Ultragenyx Announce Investigational New Drug
Press Release
Ultragenyx en LinkedIn: #raredisease
Press releases—Ultragenyx Pharmaceutical Inc.
Marin County's Ultragenyx Pharmaceutical reports Q2 loss of nearly $160 million
Foundation for Angelman Syndrome Therapeutics | FAST
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Development Pipeline – Angelman Syndrome Foundation
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharmaceutical to Distribute DOJOLVI™ (triheptanoin), for Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) - PANTHERx Rare
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy - CureDuchenne
DOJ Civil Division on X: "Pharmaceutical Company Ultragenyx Agrees to Pay $6 Million for Allegedly Paying Kickbacks to Induce Claims for Its Drug Crysvita https://t.co/Zx3qbY0FcH https://t.co/qhCWcKvyDM" / X
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx's Corporate Sustainability Journey—Ultragenyx
Ultragenyx Receives an Extended Approval for Evkeeza by the EC for 5 Years or Older Children with Homozygous Familial Hypercholesterolemia (HoFH)
Events & presentations—Ultragenyx Pharmaceutical Inc.
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
Ultragenyx Overview | SignalHire Company Profile
Ultragenyx Signs a License Agreement with Mereo for Setrusumab in Osteogenesis Imperfecta
Events & presentations—Ultragenyx Pharmaceutical Inc.
